Article

Safety of Ultrasound Contrast Agents in Patients With Known or Suspected Cardiac Shunts

Rush University Medical Center, Chicago, Illinois.
The American journal of cardiology (Impact Factor: 3.43). 06/2013; 112(7). DOI: 10.1016/j.amjcard.2013.05.042
Source: PubMed

ABSTRACT Contrast-enhanced ultrasound imaging is a radiation-free diagnostic tool that uses biocompatible ultrasound contrast agents (UCAs) to improve image clarity. UCAs, which do not contain dye, often salvage "technically difficult" ultrasound scans, increasing the accuracy and reliability of a front-line ultrasound diagnosis, reducing unnecessary downstream testing, lowering overall health care costs, changing therapy, and improving patient care. Two UCAs currently are approved and regulated by the US Food and Drug Administration. They have favorable safety profiles and risk/benefit ratios in adult and pediatric populations, including compromised patients with severe cardiovascular diseases. Nevertheless, these UCAs are contraindicated in patients with known or suspected right-to-left, bidirectional, or transient right-to-left cardiac shunts. These patients, who constitute 10% to 35% of the general population, typically receive no UCAs when they undergo echocardiography. If their echocardiographic images are suboptimal, they may receive inappropriate diagnosis and treatment, or they may be referred for additional diagnostic testing, including radiation-based procedures that increase their lifetime risk for cancer or procedures that use contrast agents containing dye, which may increase the risk for kidney damage. An exhaustive review of current peer-reviewed research demonstrated no scientific basis for the UCA contraindication in patients with known or suspected cardiac shunts. Initial safety concerns were based on limited rodent data and speculation related to macroaggregated albumin microspheres, a radioactive nuclear imaging agent with different physical and chemical properties and no relation to UCAs. Radioactive macroaggregated albumin is not contraindicated in adult or pediatric patients with cardiac shunts and is routinely used in these populations. In conclusion, the International Contrast Ultrasound Society Board recommends removal of the contraindication to further the public interest in safe, reliable, radiation-free diagnostic imaging options for patients with known or suspected cardiac shunts and to reduce their need for unnecessary downstream testing.

1 Follower
 · 
103 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis of intracardiac thrombi remains clinically relevant, with associated risks of systemic embolization and implications for antithrombotic management. Intravenously injected ultrasound contrast agents, composed of microbubbles smaller than red blood cells, have become established essential adjunctive tools for performance of state-of-the-art echocardiography, providing important information on cardiac structure and function. Despite advances in other imaging modalities, echocardiography remains the initial tool for diagnosis and risk stratification in patients predisposed to developing cardiac thrombi. Ultrasound contrast agents are approved for left ventricular (LV) opacification and endocardial border definition. Additionally, the use of contrast echocardiography facilitates LV thrombus detection by providing contrast opacification within the cardiac chambers to clearly show the "filling defect" of an intracardiac thrombus. Furthermore, contrast perfusion echocardiography can provide an assessment of the tissue characteristics of LV masses suspicious for intracardiac thrombi and, by differentiating an avascular thrombus from a tumor, results in improved diagnostic performance of echocardiography. This article presents a clinical vignette highlighting the sound judgment of using contrast echocardiography to aid in the diagnosis of LV thrombi and will review recent advances in imaging modalities for intracardiac thrombus detection.
    Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine 08/2014; 33(8):1337-44. DOI:10.7863/ultra.33.8.1337 · 1.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 2001, the American Society of Echocardiography (ASE) published a position paper that provided guidelines for the performance of contrast echocardiography by a sonographer. The paper focused on the sonographer’s role in four specific areas: understanding of microbubble physics and ultrasound instrumentation, recognition of indications for the use of contrast media, establishment of intravenous (IV) access privileges if necessary, and development of written policies for contrast agent infusion or injection. It is the purpose of this paper to update sonographers on developments in these four areas and to provide useful tips that assist in optimizing the use of contrast media in an echocardiography laboratory. This will include the optimal use of both saline and left-sided contrast media, as well as safety information and recommended policies for leftsided contrast agent use.
    Journal of the American Society of Echocardiography: official publication of the American Society of Echocardiography 08/2014; 27(8):797-810. DOI:10.1016/j.echo.2014.05.011 · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ultrasound enhancing agents (UEAs) are being utilized for a growing number of applications with real-time very low mechanical index (MI) techniques in clinical cardiology today. This article will review recent developments on the safety of UEAs and their effectiveness in myocardial perfusion imaging, three-dimensional quantification of left ventricular function, and vascular imaging. UEAs are now being utilized in all age groups, with new indications that add incremental value to the currently approved by the Food and Drug Administration. These include the incremental value in cardiac imaging, where the off-label analysis of myocardial perfusion observed with UEAs adds to the enhanced endocardial border delineation. In carotid artery imaging, UEAs improve the detection of plaque but also can examine plaque neovascularization. Vascular surgeons now utilize UEAs in the evaluation of endovascular repair to detect endoleaks without the need of ionizing radiation. Newer applications are emerging in the detection of left atrial appendage thrombi and quantification of myocardial blood flow and volume in transplant patients.
    Current Cardiology Reports 03/2015; 17(3):569. DOI:10.1007/s11886-015-0569-9

Full-text

Download
18 Downloads
Available from
Oct 28, 2014